Adaptive Biotechnologies Corp
NASDAQ:ADPT
Intrinsic Value
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. [ Read More ]
The intrinsic value of one
ADPT
stock under the Base Case scenario is
8.57
USD.
Compared to the current market price of 2.4 USD,
Adaptive Biotechnologies Corp
is
Undervalued by 72%.
ADPT's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
ADPT or that its price is influenced by factors unrelated to fundamentals.
Adaptive Biotechnologies Corp's market capitalization is 348.2m USD.
ADPT stock price is 2.4 USD.
ADPT stock price (2.4 USD) is 72% less than its Intrinsic Value (8.57 USD).
ADPT. Open DCF Valuation
ADPT has upside potential of 172% compared to the average analyst price target.
Open Wall St Estimates
ADPT's Revenue has dropped by 8% over the past 12 months.
ADPT's Revenue is forecast to grow at a rate of 20% per year over the next 3 years.
ADPT's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -48% to -61%, and is approaching profitability.
ADPT's Revenue has been growing by an exceptional 20% per year for the last 3 years.
ADPT's ROE (Return on Equity) has significantly decreased in the last 3 years from -24% to -58%, and is approaching profitability.
ADPT's long-term assets (661m USD) exceed its long-term liabilties (353m USD).
ADPT has negative Operating Income for the last twelve months.
ADPT has negative Net Income for the last twelve months.
ADPT's ROE (Return on Equity) for the past 12 months is negative and is equal to -58%.
ADPT's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -61%.
ADPT has positive Gross Profit for the last twelve months.
ADPT has negative Free Cash Flow for the last twelve months.
ADPT has negative three-year average ROE (Return on Equity): -36%. The company is not efficient at transforming stockholders' equity into net income.
ADPT has negative three-year average ROIC (Return on Invested Capital): -49%. The company is not efficient at using invested capital to generate operating income.
ADPT's short-term assets (410m USD) exceed its short-term liabilties (88m USD).
ADPT's D/E (Debt to Equity) is very low and is equal to 0.
ADPT's Altman Z-Score is very low and is equal to -2.01.
ADPT doesn't generate enough operating income (-202m USD) to safely cover interest payments on its debt (7m USD).
Valuation Backtest
Adaptive Biotechnologies Corp
Run backtest to discover the historical profit from buying and selling
ADPT
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Adaptive Biotechnologies Corp
Balance Sheet Decomposition
Adaptive Biotechnologies Corp
| Current Assets | 410.2m |
| Cash & Short-Term Investments | 346.4m |
| Receivables | 38m |
| Other Current Assets | 25.8m |
| Non-Current Assets | 250.9m |
| PP&E | 120.3m |
| Intangibles | 124.1m |
| Other Non-Current Assets | 6.5m |
| Current Liabilities | 88m |
| Accounts Payable | 7.7m |
| Accrued Liabilities | 31.7m |
| Other Current Liabilities | 48.6m |
| Non-Current Liabilities | 264.7m |
| Other Non-Current Liabilities | 264.7m |
Earnings Waterfall
Adaptive Biotechnologies Corp
|
Revenue
|
170.3m
USD
|
|
Cost of Revenue
|
-75.6m
USD
|
|
Gross Profit
|
94.7m
USD
|
|
Operating Expenses
|
-296.3m
USD
|
|
Operating Income
|
-201.6m
USD
|
|
Other Expenses
|
-23.6m
USD
|
|
Net Income
|
-225.3m
USD
|
Free Cash Flow Analysis
Adaptive Biotechnologies Corp
What is Free Cash Flow?
ADPT Profitability Score
Profitability Due Diligence
Adaptive Biotechnologies Corp's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Adaptive Biotechnologies Corp's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
ADPT Solvency Score
Solvency Due Diligence
Adaptive Biotechnologies Corp's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Score
Adaptive Biotechnologies Corp's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ADPT Price Targets Summary
Adaptive Biotechnologies Corp
According to Wall Street analysts, the average 1-year price target for
ADPT
is 6.53 USD
with a low forecast of 5.05 USD and a high forecast of 10.5 USD.
Ownership
ADPT Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ADPT Price
Adaptive Biotechnologies Corp
| Average Annual Return | -14.57% |
| Standard Deviation of Annual Returns | 72.25% |
| Max Drawdown | -97% |
| Market Capitalization | 351.1m USD |
| Shares Outstanding | 145 092 000 |
| Percentage of Shares Shorted | 8.04% |
Company Profile
Adaptive Biotechnologies Corp
Country
Industry
Market Cap
Dividend Yield
Description
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington and currently employs 858 full-time employees. The company went IPO on 2019-06-27. The firm is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform combines a suite of chemistry, biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its commercial research products include immunoSEQ and immunoSEQ T-MAP. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). Its clonoSEQ diagnostic test detects and monitors the number of cancer cells that are present in a patient’s body during and after treatment, known as minimal residual disease (MRD). The company uses its T cell receptor (TCR)-Antigen Map to develop research solutions and diagnostic products, such as immunoSEQ T-MAP and T-Detect. The company also focuses on developing immune-mediated therapies in oncology and other disease areas.
Contact
IPO
Employees
Officers
The intrinsic value of one
ADPT
stock under the Base Case scenario is
8.57
USD.
Compared to the current market price of 2.4 USD,
Adaptive Biotechnologies Corp
is
Undervalued by 72%.
You don't have any saved screeners yet
